Telix Pharmaceuticals (TLX) said Tuesday that it received a subpoena from the US Securities and Exchange Commission asking for documents and information related to disclosures regarding the development of the company's prostate cancer treatments.
The company said it is fully cooperating with the SEC and is in the process of responding to the information request.
Telix also said it decided to notify the Australian Securities and Investments Commission of the SEC's request.
Price: 16.67, Change: +0.07, Percent Change: +0.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.